Bright Minds Biosciences Stock Revenue
| DRUG Stock | USD 33.63 0.14 0.41% |
Fundamental analysis of Bright Minds allows traders to better anticipate movements in Bright Minds' stock price by examining its financial health and performance throughout various phases of its business cycle.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Bright Minds Biosciences Company Revenue Analysis
Bright Minds' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Bright Minds Biosciences reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Bright Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bright Minds' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bright Minds could also be used in its relative valuation, which is a method of valuing Bright Minds by comparing valuation metrics of similar companies.Bright Minds is currently under evaluation in revenue category among its peers.
Bright Fundamentals
| Return On Equity | -0.11 | ||||
| Return On Asset | -0.11 | ||||
| Current Valuation | 196.23 M | ||||
| Shares Outstanding | 7.08 M | ||||
| Shares Owned By Insiders | 22.54 % | ||||
| Shares Owned By Institutions | 74.81 % | ||||
| Number Of Shares Shorted | 169.04 K | ||||
| Price To Book | 5.91 X | ||||
| EBITDA | (7.28 M) | ||||
| Net Income | (2.8 M) | ||||
| Cash And Equivalents | 8.64 M | ||||
| Cash Per Share | 0.71 X | ||||
| Total Debt | 118.96 K | ||||
| Current Ratio | 22.88 X | ||||
| Book Value Per Share | 7.87 X | ||||
| Cash Flow From Operations | (1.85 M) | ||||
| Short Ratio | 2.74 X | ||||
| Earnings Per Share | (0.40) X | ||||
| Target Price | 93.67 | ||||
| Beta | 0.23 | ||||
| Market Capitalization | 239.2 M | ||||
| Total Asset | 6.1 M | ||||
| Retained Earnings | (34.35 M) | ||||
| Working Capital | 5.46 M | ||||
| Net Asset | 6.1 M |
About Bright Minds Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bright Minds Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bright Minds using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bright Minds Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Check out Bright Minds Piotroski F Score and Bright Minds Altman Z Score analysis. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bright Minds. If investors know Bright will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bright Minds listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bright Minds Biosciences is measured differently than its book value, which is the value of Bright that is recorded on the company's balance sheet. Investors also form their own opinion of Bright Minds' value that differs from its market value or its book value, called intrinsic value, which is Bright Minds' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bright Minds' market value can be influenced by many factors that don't directly affect Bright Minds' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bright Minds' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bright Minds is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bright Minds' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.